Study on low blood cell counts after chemotherapy in county-level cancer patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how common low blood cell counts (myelosuppression) are after chemotherapy and how it is managed in Chinese hospitals. If you are getting chemotherapy for certain cancers, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with one of these cancers: non-small cell lung, small cell lung, breast, stomach, esophagus, colorectal, ovarian, cervical, or endometrial cancer.
- You have received chemotherapy in the past 3 months and will continue it in the future.
- You had at least 1–2 blood tests done about a week after your last chemo.
- Your current or most recent chemo regimen must be one of the standard ones listed in the study (e.g., platinum-based, taxane-based, etc.).
- You are willing and able to give informed consent.
- You cannot be in this study if you are also getting radiation at the same time or had radiation to your pelvis, sternum, or flat bones recently, or have active bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This study follows people with ongoing low blood counts (red cells, white cells, and/or platelets) to better understand their condition when it does not meet criteria for MDS. It may help improve how persistent blood count problems are evaluated over time.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This study compares different doses of a medication called PEG-rhG-CSF, which is used to help prevent a serious side effect of chemotherapy called febrile neutropenia (fever with a low white blood cell count). The goal is to find the best dose that keeps your blood counts healthy and reduces the risk of infection during treatment.
This trial tests whether infusing stem cells from umbilical cord blood can help your bone marrow recover and make healthy blood cells again after chemotherapy. The goal is to improve your blood counts and reduce the need for transfusions.
This study looks at how a type of white blood cell in your blood changes while you receive radiation and chemotherapy. The goal is to see whether these blood changes relate to treatment, especially in certain chest (thoracic) cancers.
Hear when a new Myelosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.